Formycon Raises Fresh Capital To Drive Biosimilar Development
Funding For COVID-19 Also Received
German biosimilars firm Formycon has raised tens of millions of euros through an issue of new shares, with the cash earmarked for its burgeoning pipeline of wholly-owned biosimilars, including a Lucentis (ranibizumab) candidate being developed with Coherus.
You may also be interested in...
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.
Biosimilar Lucentis in Europe is once again in the headlines, as Teva announced a deal to in-license Bioeq and Formycon’s FYB201 ranibizumab candidate in several key global markets.
Achieving superior stability profiles, leading to additional value propositions for development projects, is the aim of the game for Formycon and Leukocare under a new strategic development agreement.